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CLINICAL PRESENTATION
Cervical cancer is an increasingly rare cancer in the United
Kingdom because of the success of the National Screening
Programme. It is much less likely to occur in previously screened
women than unscreened women and although it most commonly
presents with clinical symptoms, it may be identified during the
investigation of a screening cytology abnormality, that is, by
colposcopy. When it presents clinically, this usually involves
abnormal patterns of vaginal bleeding in premenopausal women or
postmenopausal bleeding in older women. There may also be an
unpleasant vaginal discharge. When the cancer is more advanced it
may present with low abdominal or buttock pain due to pressure
on the lumbosacral nerve plexus.
DIAGNOSIS AND TREATMENT
Carcinoma of the cervix is usually clinically obvious on
gynaecological examination and a small biopsy may be sufficient
to confirm the diagnosis and determine the histotype. On the
occasions when it is screen detected, that is, only detected because
the affected woman had a routine cervical smear test, it may not
be clinically apparent and may require a colposcopic examination.
Under these circumstances the tumour may be very early in its
natural history, at the microinvasive stage, and requires a so-called
‘cone biopsy’ to assess both depth of invasion and lesion width.
There are two main elements in the diagnostic process, which
enable optimal treatment planning:
(1) To stage the disease using the FIGO staging system, by
evaluating its extent by means of thorough clinical examination,
chest X-ray and possibly cystoscopic examination. Magnetic
resonance scanning is a valuable supplement to clinical staging
particularly in determining the local extent of tumour and
identifying obvious node enlargement.
(2) To determine the histotype for example, squamous or
adenocarcinoma, the degree of differentiation and the
presence of lymph vascular channel involvement.
During the past 20 years, three key developments have taken
place in cervical cancer management. The most significant
therapeutic advance has been the advent of chemoradiation, in
which a relatively small dose of platinum chemotherapy is given
weekly, concurrently, with external beam radiation. A number of
randomised trials published in 1999 confirmed a significant
survival benefit for chemoradiation and this has been the
recommended standard of care since 2000 in the United Kingdom.
The second development has been fertility sparing surgery, which
is most appropriate for women who wish to retain fertility and who
have tumours less than 2cm across. In such cases the uterine
corpus can be retained and a successful pregnancy may result. The
third development, and in some way the most important, has been
the determination and national guidance that the management of
cervical cancer should be undertaken by specialised multidisci-
plinary teams. This has improved access to accurate pathological
diagnosis, expert treatment planning, and specialised surgical and
non-surgical oncological care (NHS Executive, 1999). There was
evidence in the past that access to expert care was unequal with
unequal outcomes (Wolfe et al, 1996) but with the full
implementation of Improving Outcomes Guidance, this should
be resolved.
INTERPRETATION OF SURVIVAL PATTERNS
Improvements in survival may reflect either a shift in stage
towards diagnosis earlier in the natural history of cancer,
therapeutic advances, or improvement in access to best care. In
cervical cancer all three apply, with more screen-detected early
disease, improved treatment of advanced disease with chemo-
radiation and widespread access to expert teams in gynaecological
cancer centres.
One-year survival is probably determined by the proportion of
women who present either with very aggressive disease, which is
unresponsive to treatment, or such advanced disease that optimal
therapy is not possible. Five-year survival is more a measure of
(a) stage at diagnosis that determines the proportion of curable
tumours and (b) quality of therapy, which achieves longer lasting
control. In general, if cancer of the cervix relapses, this generally
occurs within 3 years and recurrence thereafter is unusual. The
treatment of recurrence is usually surgical salvage or irradiation in
previously non-irradiated patients but either way the results are
poor, overall.
The improvement in 1- and 5-year survival rates during the
1970s and 1980s could well be due to improved access to expert
radiotherapy and to improved healthcare generally, which means
fewer untreatable women at presentation. The effect of a highly
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cantly over the past 40 years. The improvement in survival in the
women diagnosed between 1986 and 1990 possibly reflects a larger
proportion being screen detected, that is, some early prevalent
disease being picked up at a more curable stage by the outset in
1988 of the National Cervical Screening Programme. This effect
will have been sustained during the 1990s. The lack of any increase
in survival since then is probably a reflection of the stable 20% or
so of the female population who decline to take up cervical
screening. Any significant and widely implemented advances in
treatment up to the late 1990s, may result in modest improvements
in survival; for example, as a result of national adoption of
chemoradiation. Only time will tell but the projected survival data
do not apparently point to this.
DEPRIVATION GAP
Cancer of the cervix remains a more prevalent disease among
socially deprived women. This is probably due to a combination of
riskier lifestyle behaviour such as cigarette smoking, earlier onset
of sexual intercourse and most importantly, poorer uptake of
cervical screening. Other influences during the last 10 years, which
may be associated with social deprivation are HIV-positive women
and unscreened immigrant populations. There is little evidence
that any of these risk factors, which are more prevalent among
socially deprived women, have changed suggesting a low likelihood
of a reduction in incidence rates. Survival will be influenced by
screening, as screen detected cancers are generally at an earlier
stage, and up until 2000 access to optimal cancer care was uneven
across the country.
CLOSING THE DEPRIVATION GAP
Incidence
Greater awareness of sexual health, reduced smoking habit and
education regarding cervical screening are all key to reducing the
risk of acquiring cervical cancer.
Vaccination against HPV, however, has the greatest potential to
reduce deaths from cervical cancer by preventing genital infection
by the high-risk oncotypes of HPV, particularly 16 and 18. It is
generally reckoned that worldwide, these HPV strains are respon-
sible for approximately 70% of cervical cancer. If these infections
were prevented then the precursor lesions of cervical cancer and the
cancer itself should be prevented. Recent publications from two
major global trials of prophylactic vaccines against HPV 16 and 18
indicate that HPV vaccines are highly effective at preventing type
specific infection and type specific cervical intraepithelial neoplasia.
The data from these trials have resulted in a commitment from the
UK Government, among others, to provide funding for a national
vaccination programme of 12- to 13-year-old females, with a one-off
catch-up to the age of 18 years over a 3-year period. There are a
number of unknowns at the moment, which require further work.
These include longevity of vaccine protection, cross coverage of the
other HPV types and whether prior HPV exposed women, not
currently infected with HPV 16 or 18, can be protected by
preventing re-infection. Any impact this has on cervical cancer
death rates would take years to be felt but vaccinating older females
on the threshold of cervical screening could have a more rapid
impact in terms of reduced incidence of CIN. Because HPV 16 and
18 are only responsible for 60% of CIN3, cervical screening will
need to continue and with new protocols considered.
Survival
The best opportunity to influence survival will be a trend towards
earlier presentation, brought about by better screening, resulting
in more screen-detected cases and with fewer advanced cases
presenting only after the establishment of abnormal bleeding and
pain. Screen detected cancers are relatively less common in
deprived areas of the West Midlands (G Lawrence, personal
communication) and this will have an impact on survival.
Universal access for all women to receive care in a specialist
centre for cervical cancers as a result of the Cancer Plan, means
that optimal care should be provided to socially deprived women,
improving disease outcomes. Nevertheless, screening offers the
strongest strategy to close the deprivation gap in survival.
Overall comment
Death rates from cervical cancer have fallen dramatically over the
past 20 years and for those unfortunate enough to acquire the
disease, survival has improved. The deprivation gap in incidence
would reduce if more women avoided tobacco and attended
screening. With respect to survival, more screen detection of early
cancer, through greater uptake of screening, access to optimal
therapy and centralised expert multidisciplinary care, combine to
offer the opportunity to close the deprivation gap.
A national audit of cervical cancers is urgently required to map
the disease in terms of stage, and to identify why the means to
prevent this preventable disease have failed. Ultimately, cervical
cancer could be virtually eradicated though prophylactic vaccina-
tion of young adolescents combined with appropriate cervical
screening from the age 25. Implementing a successful vaccination
policy will be challenging but it may be the best hope for
protecting all women.
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